结论 文章要点 研究背景 目前,关于解剖女性直肠前壁的方法还没有全面的描述。由于缺乏适当的解剖平面,许多外科医生遇到术中出血的情况。 研究动机 在女性患者的全直肠系膜切除手术中,游离直肠前壁的手术方法仍有争议。然而,随着对盆腔解剖的更深刻理解,我们可以确定无血管平面,减少术中出血并防止对生理结构的伤害。 研究目标 我们旨在更好地了解女性盆腔的解剖结构,以确定剖开直肠前壁的最佳方法。这将有利于改善中、低位直肠癌女性患者的手术效果。 研究方法 首先,我们在回顾了手术视频后,根据不同的方法对患者进行了回顾性分组。收集了临床信息,比较了术前和术后的数据,同时回顾了手术视频,以了解解剖学和术中情况。随后,通过尸体解剖和组织学切片研究了女性盆腔结构。 研究成果 我们发现,在腹膜反折的最低点打开腹膜可以进入阴道外膜和直肠系膜之间的平面。在腹膜反折上方0.5-1厘米处打开腹膜,进入位于阴道内膜和阴道肌肉层之间的另一个平面。与第二种方法相比,第一种方法的术中出血量较少,住院时间较短。尸体解剖和病理检查都没有发现Denonvilliers筋膜的存在。在直肠骶骨筋膜和阴道外膜之间只存在松散的结缔组织。 研究结论 女性没有Denonvilliers筋膜。直肠系膜和阴道外膜之间的平面是游离女性患者直肠前壁的最佳手术平面。 研究视角 在未来的研究中,我们将探索这两种方法对女性的长期预后,以及对术后性和阴道功能的影响。 鸣谢 感谢李新宇、李秧秧和杨新东对我们工作的巨大贡献。 ▼滑动查看参考文献 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249 2. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J et al. Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1558–1571 3. Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol 2020;5:475–484 4. Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020;395:123–131 5. Morris VK, Kennedy EB, Baxter NN, Benson AB, Cercek A, Cho M et al. Treatment of metastatic colorectal cancer: ASCO guideline.J Clin Oncol 2023;41:678–700 6. You YN, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum 2020;63:1191–1222 7. Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum 2022;65:148–177 8. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome. Colorectal Dis 2009;11:354–364 9. Heald R, Ryall RD. Recurrence and survival after total mesorectal exicision for rectal cancer. Lancet 1986;327: 1479–1482 10. Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection.Cochrane Database Syst Rev 2008; (2)CD003432 11. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ.Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 2010;97:1638–1645 12. Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer. Ann Surg 2019;269:589–595 13. Hsieh C, Cologne KG. Laparoscopic approach to rectal cancer—the new standard? Front Oncol 2020;10:1239 14. Klein MF, Vogelsang RP, Gögenur I. Circumferential resection margin after laparoscopic and open rectal resection: a nationwide propensity score matched cohort study. Dis Colon Rectum 2019;62:1177–1185 15. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery. JAMA Surg 2017;152:292 16. Molenaar CJL, van Rooijen SJ, Fokkenrood HJP, Roumen RMH, Janssen L, Slooter GD. Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery. Cochrane Database Syst Rev 2022; (5)CD013259 17. Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol 2021;22:43–50 18. Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023;41:1541–1552 19. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1291–1305 20. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol 2022;40:892–910 21. Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26:566–576 22. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363–2376
|
|